Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
|Articles|October 1, 2005
- Volume 0 0
Diabetes Product Charts
Advertisement
Articles in this issue
almost 21 years ago
A Pharmacist's Guide to OTC Therapy: Ocular Care Productsalmost 21 years ago
Dangerous Liaisons: Schizophrenia and Diabetesalmost 21 years ago
A Pharmacist's Guide to OTC Therapy: Diabetic Nutritional Supplementsalmost 21 years ago
Tarceva Extends Lung Cancer Survivalalmost 21 years ago
Inhaled Morphine Aids Cancer-related Dyspneaalmost 21 years ago
Diuretic Best BP Therapy for African Americansalmost 21 years ago
A Pharmacist's Guide to OTC Therapy: Diabetic Foot Care Productsalmost 21 years ago
New Drug Blocks Out AIDS Virusalmost 21 years ago
Viagra Ingredient Has Another Usealmost 21 years ago
GUEST COMMENTARY: FIGHTING THE NEW PHARMACOPHOBIAAdvertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
4
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
5